Literature DB >> 8763841

Multicellular membranes as an in vitro model for extravascular diffusion in tumours.

D S Cowan1, K O Hicks, W R Wilson.   

Abstract

Efficient extravascular diffusion is a critical requirement for hypoxic cell radiosensitisers, bioreductive drugs and hypoxic cell markers that must reach cells distant from functional blood vessels in tumours. The diffusion of simple nitroimidazoles with neutral (misonidazole, miso) and basic (pimonidazole, pimo) side chains, as well as 2-nitroimidazoles with acridine (NLA-1) and phenanthridine (2-NLP-3) DNA intercalating moieties was investigated using multicellular membranes (MMs), a new in vitro model for the extravascular compartment of tumours. The diffusion of miso through V79 MMs was concentration independent over the range 0.1-10 mM. Mathematical modelling of the flux kinetics provided a diffusion coefficient in MMs (DMM) of 5.5 x 10(-7) cm2 s-1 which was approximately 13-fold lower than in culture medium. Flux was little affected by the extent of hypoxia in MMs, indicating that hypoxic metabolism does not compromise diffusion of miso over distances in the order of 200 microns. The DMM for pimo was similar to miso, while those for 2-NLP-3 and NLA-1 were both lower. The results demonstrate compromised extravascular diffusion for DNA-intercalating nitroimidazoles, but indicate that this problem is more severe for the basic acridine derivative, NLA-1, than for the phenanthridine, 2-NLP-3. The MM model appears to be well suited to quantitative determination of drug diffusion in a multicellular environment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763841      PMCID: PMC2149990     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  11 in total

1.  NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation.

Authors:  W A Denny; P B Roberts; R F Anderson; J M Brown; D Phil; W R Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids.

Authors:  M Erlanson; E Daniel-Szolgay; J Carlsson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

Authors:  T Nederman; J Carlsson
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Two-dimensional diffusion limited system for cell growth.

Authors:  L Hlatky; E L Alpen
Journal:  Cell Tissue Kinet       Date:  1985-11

5.  Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.

Authors:  J J Casciari; M G Hollingshead; M C Alley; J G Mayo; L Malspeis; S Miyauchi; M R Grever; J N Weinstein
Journal:  J Natl Cancer Inst       Date:  1994-12-21       Impact factor: 13.506

6.  Reductive metabolism and hypoxia-selective toxicity of nitracrine.

Authors:  W R Wilson; W A Denny; G M Stewart; A Fenn; J C Probert
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

7.  Comparison of binding of [3H]misonidazole and [14C]misonidazole in multicell spheroids.

Authors:  J S Rasey; Z Grunbaum; K Krohn; N Nelson; L Chin
Journal:  Radiat Res       Date:  1985-03       Impact factor: 2.841

8.  Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix.

Authors:  W Dang; O M Colvin; H Brem; W M Saltzman
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids.

Authors:  A J Franko
Journal:  Radiat Res       Date:  1985-07       Impact factor: 2.841

10.  DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies.

Authors:  D S Cowan; J F Matejovic; R A McClelland; A M Rauth
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more
  18 in total

1.  A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors.

Authors:  Nelita T Elliott; Fan Yuan
Journal:  Biotechnol Bioeng       Date:  2011-12-26       Impact factor: 4.530

2.  Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models.

Authors:  Mohammad H El-Dakdouki; Ellen Puré; Xuefei Huang
Journal:  Nanoscale       Date:  2013-04-03       Impact factor: 7.790

3.  Modeling of oxygen transport across tumor multicellular layers.

Authors:  Rod D Braun; Alexis L Beatty
Journal:  Microvasc Res       Date:  2006-12-27       Impact factor: 3.514

4.  Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones.

Authors:  Venugopal Marasanapalle; Xiaoling Li; Lisa Polin; Bhaskara R Jasti
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

Review 5.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles.

Authors:  Seiji Miura; Hidenori Suzuki; You Han Bae
Journal:  Nano Today       Date:  2014-12-01       Impact factor: 20.722

8.  Characterization of three-dimensional tissue cultures using electrical impedance spectroscopy.

Authors:  A H Kyle; C T Chan; A I Minchinton
Journal:  Biophys J       Date:  1999-05       Impact factor: 4.033

9.  Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.

Authors:  Rama H Grantab; Ian F Tannock
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

10.  The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

Authors:  Annika Foehrenbacher; Kashyap Patel; Maria R Abbattista; Chris P Guise; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-10-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.